Key result
Paclitaxel-coated balloons show similar in-hospital adverse outcomes to DES for in-stent restenosis.
Why the study?
AGENT is the only coronary drug-coated balloon approved for in-stent restenosis to date, prompting an evaluation of trends in use, characteristics, and in-hospital outcomes compared with alternative treatments.
What are the real-world utilization trends and in-hospital outcomes of paclitaxel-coated balloons compared with standard treatments for percutaneous coronary intervention in the United States?
Observational (n=906,935)
Yes
What are the real-world utilization trends and in-hospital outcomes of paclitaxel-coated balloons compared with standard treatments for percutaneous coronary intervention in the United States?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The approval of this device will change the standard of care for patients with ISR; however, it won't be the go-to approach for all patients. This is just another tool in our arsenal that we can use when treating these patients.”
“When we do a landmark analysis, we see that most of the benefit, in fact all of the benefit, was achieved in the first year, with comparable growth of the curves after that 1-year mark, perhaps as might be expected for a treatment that is not durable per se”
“For patients with in-stent restenosis, paclitaxel-coated balloons will be an important and effective new therapy, superior to uncoated balloon angioplasty. Importantly, for high-risk patients with multiple prior stents at the site of the restenosis, where additional stenting would reduce lumen area and not be ideal, paclitaxel-coated technology will become first-line therapy for in-stent restenosis.”
Following FDA approval, real-world paclitaxel drug-coated balloon utilization is growing rapidly in the United States with high use in complex lesions and an early in-hospital safety profile comparable to traditional devices.
BACKGROUND: AGENT is the only coronary drug-coated balloon (DCB) approved for treatment of in-stent restenosis (ISR) to date. In this study, we describe trends in DCB use and compare characteristics and in-hospital outcomes between patients who received DCB versus alternative treatments. METHODS: We included patients in the American College of Cardiology National Cardiovascular Disease Registry CathPCI Registry who underwent percutaneous coronary intervention between April 2024 and June 2025 and received DCB, drug-eluting stent (DES), or plain old balloon angioplasty. Treatment groups were compared using standard mean differences. RESULTS: Between April 2024 and June 2025, 14 946 DCBs were used in 12 337 patients across 704 CathPCI Registry sites. The monthly rate of DCB use for ISR percutaneous coronary intervention grew from <1% to 17.5% during the study period. Of 96 452 ISR procedures performed overall, 9269 (9.61%) involved the use of DCB. DCB procedures were more likely to involve the use of specialty balloons (DCB 45.3% versus DES 17.5% versus plain old balloon angioplasty 28.3%), intravascular imaging (DCB 54.5% versus DES 35.1% versus plain old balloon angioplasty 30.9%), and atherectomy (DCB 14.9% versus DES 6.0% versus plain old balloon angioplasty 7.3%). Among patients treated with DCB, 0.4% experienced myocardial infarction, 0.7% developed cardiogenic shock, 0.2% had an ischemic stroke, and 0.9% died. DCB was separately used in 3459 of 810 483 (0.43%) non-ISR percutaneous coronary interventions. Unadjusted rates of in-hospital adverse outcomes after ISR and non-ISR DCB use were like those for DES (standard mean difference <10%). CONCLUSIONS: Real-world DCB use is increasing rapidly in the United States, driven by use in ISR lesions but also with growth among non-ISR lesions.
No takes yet. Share an insight, caveat, or question.
Lalani et al. (2026) conducted an observational in In-stent restenosis (ISR) and non-ISR coronary lesions requiring percutaneous coronary intervention (n=906,935). Paclitaxel-coated balloons vs. Drug-eluting stents (DES) and plain old balloon angioplasty (POBA) was evaluated on In-hospital adverse outcomes (including all-cause mortality, myocardial infarction, cardiogenic shock, and ischemic stroke) (SMD <10%). Real-world paclitaxel-coated balloon use rapidly increased in the US, accounting for 9.61% of in-stent restenosis procedures, with in-hospital adverse outcomes similar to drug-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: